top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIgE/hFCER1A mice
Strain Name
C57BL/6N-Ighetm1(IGHE)BcgenFcer1atm1(FCER1A)Bcgen/Bcgen
Common Name  B-hIgE/hFCER1A mice
Background C57BL/6N Catalog number 111891
Related Genes 
IGHE, IgE; FCER1A, FCE1A, FcERI, Fc fragment of IgE receptor Ia
Protein expression analysis in basophils 

from clipboard


Strain specific IgE expression analysis in homozygous B-hIgE/hFCER1A mice by flow cytometry. Basophilic granulocytes of the bone marrow were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hIgE/hFCER1A mice (H/H;H/H) stimulated with LPS in vivo, and analyzed by flow cytometry with species-specific anti-IgE antibody. Mouse IgE was detectable in WT mice (+/+). Human IgE was exclusively detectable in homozygous B-hIgE/hFCER1A mice (H/H;H/H) but not in WT mice (+/+).

from clipboard


Strain specific FCER1A expression analysis in homozygous B-hIgE/hFCER1A mice by flow cytometry. Basophilic granulocytes of the bone marrow were collected from wild type (WT) mice (+/+) and homozygous B-hIgE/hFCER1A mice (H/H;H/H), and analyzed by flow cytometry with species-specific anti-FCER1A antibody. Mouse FCER1A was detectable in WT mice (+/+). Human FCER1A was exclusively detectable in homozygous B-hIgE/hFCER1A mice (H/H;H/H) but not in WT mice (+/+).


Omalizumab alleviated OVA induced active systemic anaphylaxis (ASA) in B-hIgE/hFCER1A mice


from clipboard


Effects of Omalizumab on OVA induced ASA. B-hIgE/hFCER1A mice (H/H; H/H) received OVA/Al(OH)3 immunization on day 0, and challenge with OVA on day 14. Omalizumab (in house) was injected 3 hour before challenge on day 14. (A) The body temperature of the mice was recorded from 0 to 90 minutes after the challenge. (B) An increasing trend was produced by Omalizumab (in house) in the ASA model. It can be seen that Omalizumab (in house) has an inhibitory effect on the decrease in body temperature caused by ASA modeling in B-hIgE/hFCER1A mice (H/H; H/H).